Early-Stage Results with Transcatheter Tricuspid-Valve Replacement

The past two decades have witnessed a renaissance in the evaluation and treatment of patients with valvular heart disease, catalyzed by advances in surgical innovation, transcatheter techniques, and multimodality cardiac imaging. Transcatheter aortic-valve replacement (TAVR) has been accepted as a reasonable alternative to surgical aortic-valve replacement for the treatment of older patients with severe aortic stenosis; mitral transcatheter edge-to-edge repair (M-TEER) can be safely and effectively used to treat select patients with primary or secondary mitral regurgitation. Tricuspid regurgitation has been a more recent focus of intense clinical investigation. New systems for classifying the cause and severity of tricuspid regurgitation . . .